Qihan Biotech gains FDA momentum for QT-019B as allogeneic CAR-T ambitions grow
Find out how Qihan Biotech’s QT-019B FDA designations could reshape autoimmune CAR-T development and what risks remain.
Pharma & Biotech
Pharma & Biotech
Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
Find out how Cartesian Therapeutics’ WestGene deal could reshape in vivo CAR-T strategy in autoimmune disease and what risks remain.
Pharma & Biotech
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.